Inducible p27Kip1 expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors

Cell Death and Differentiation

Volumn 10, Issue 3, 2003, Pages 290-301

  Drexler, Hennes C A ^a   Pebler, S ^a  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Apoptosis; Cell cycle; Leukemia; p27kip1; Proteasome inhibitor

Indexed keywords

APHIDICOLIN; BENZYLOXYCARBONYLISOLEUCYL GAMMA TERT BUTYL GLUTAMYLALANYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOXYCYCLINE; EPOXOMICIN; PROTEASOME INHIBITOR; PROTEIN P27; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY ANALYSIS; TUMOR CELL; WILD TYPE;

ANTIBIOTICS, ANTINEOPLASTIC; APHIDICOLIN; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL NUCLEUS; CELL SEPARATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLOW CYTOMETRY; GENETIC VECTORS; HEMOGLOBINS; HUMANS; K562 CELLS; LEUPEPTINS; MICROSCOPY, FLUORESCENCE; MODELS, GENETIC; MULTIENZYME COMPLEXES; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RETROVIRIDAE; S PHASE; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 0038297042     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401159     Document Type: Review

References (79)

1. Hershko A and Ciechanover A. (1998) The ubiquitin system. Annu. Rev. Bochem. 67: 425-479
2. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771
3. Drexler HCA (1997) Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA 94: 855-860
4. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S and Kikuchi H (1995) Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun. 217: 1070-1077
5. Fujita T, Ishido S, Muramatsu S, Itoh M and Hotta H (1996) Suppression of actinomycin D-induced apoptosis by the Ns3 protein of hepatitis C virus. Biochem. Biophys. Res. Commun. 229: 825-831
6. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H and Kawashima S (1996) Apoptosis induction resulting from proteasome inhibition. Biochem. J. 317: 385-388
7. Tanimoto Y, Onishi Y, Hashimoto S and Kizaki H (1997) Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma Rvc cells. J. Biochem. 121: 542-549
8. An B, Goldfarb RH, Siman R and Dou QP (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5: 1062-1075
9. Dietrich C, Bartsch T, Schanz F, Oesch F and Wieser RJ (1996) p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl. Acad. Sci. USA 93: 10 815-10 819
10. Lopes UG, Erhardt P, Yao RJ and Cooper GM (1997) p53-dependent induction of apoptosis by proteasome inhibitors, J. Biol. Chem. 272: 12 893-12 896
11. Blagosklonny MV, Wu GS, Omura S and Eldeiry WS (1996) Proteasome-dependent regulation of p21(Waf1/Cip1) expression. Biochem. Biophys. Res. Comm. 227: 564-569
12. Cayrol C and Ducommun B (1998) Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 17: 2437-2444
13. Pagano M, Tam SW, Theodoras AM, Beerromero P, Delsal G, Chau V, Yew PR, Draetta GF and Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685
14. Kisselev AF and Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8: 739-758
15. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59: 2615-2622
16. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C (2001) Novel proteasome inhibitor PS-341 inhibits activation of Nuclear Factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7: 1419-1428
17. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61: 3071-3076
18. Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP and Sebti SM (2001) CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 61: 1280-1284
19. Sadoul R, Fernandez P-A, Quiquerez A-L, Martinou I, Maki M, Schröter M, Becherer JD, Irmler M, Tschopp J and Martinou J-C (1996) Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 15: 3845-3852
20. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM and Osborne BA (1996) Proteasomes play an essential role in thymocyte apoptosis. EMBO J. 15: 3835-3844
21. Drexler HCA, Risau W and Konerding MA (2000) Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells. FASEB J. 14: 65-77
22. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8: 9-22
23. Hirano M, Hirano K, Nishimura J and Kanaide H (2001) Transcriptional up-regulation of p27(Kip1) during contact-induced growth arrest in vascular endothelial cells. Exp. Cell Res. 271: 356-367
24. Suzuki E, Nagata D, Yoshizumi M, Kakoki M, Goto A, Omata M and Hirata Y (2000) Reentry into the cell cycle of contact-inhibited vascular endothelial cells by a phosphatase inhibitor. Possible involvement of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J. Biol. Chem. 275: 3637-3644
25. Hofmann F, Martelli F, Livingston DM and Wang ZY (1996) The retinoblastoma gene product protects E2f-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10: 2949-2959
26. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR and Cotter TG (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179-1187
27. Benito A, Silva M, Grillot D, Nunez G and Fernandez-Luna JL (1996) Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-xL. Blood 87: 3837-3843
28. Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J and Aulitzky WE (2000) Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 96: 1933-1939
29. Gesbert F, Sellers WR, Signoretti S, Loda M and Griffin JD (2000) BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J. Biol. Chem. 275: 39 223-39 230
30. Dan S, Naito M and Tsuruo T (1998) Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5: 710-715
31. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J et al. (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175-185
32. Shuai K, Halpern J, ten Hoeve J, Rao X and Sawyers CL (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13: 247-254
33. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B and Calabretta B (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86: 726-736
34. Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE and Toyama K (1995) Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp. Hematol. 23: 1153-1159
35. Sawyers CL, Callahan W and Witte ON (1992) Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70: 901-910
36. Mandanas RA, Boswell HS, Lu L and Leibowitz D (1992) BCR/ABL confers growth factor independence upon a murine myeloid cell line. Leukemia 6: 796-800
37. Katayose Y, Kim M, Rakkar ANS, Li ZW, Cowan KH and Seth P (1997) Promoting apoptosis - a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 57: 5441-5445
38. Wang X, Gorospe M, Huang Y and Holbrook NJ (1997) p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 15: 2991-2997
39. Schreiber M, Muller WJ, Singh G and Graham FL (1999) Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18: 1663-1676
40. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, Zhao M, Miyauchi M and Nikai H (2000) p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 6: 916-923
41. An B, Goldfarb RH, Siman R and Dou QP (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5: 1062-1075
42. Kobayashi T, Ruan SB, Clodi K, Kliche KO, Shiku H, Andreeff M and Zhang W (1998) Overexpression of bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 16: 1587-1591
43. Cummings M, Siitonen T, Higginbottom K, Newland AC and Allen PD (2002) p53-mediated downregulation of Chk1 abrogates the DNA damage-induced G2 M checkpoint in K562 cells, resulting in increased apoptosis. Br. J. Haematol. 116: 421-428
44. Di Bacco AM and Cotter TG (2002) p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. Br. J. Haematol. 117: 588-597
45. Kobayashi T, Sawa H, Morikawa J, Ueno S, Katayama N, Zhang W and Shiku H (2002) Bax-induction alone is sufficient to activate apoptosis cascade in wild-type Bax-bearing K562 cells, and the initiation of apoptosis requires simultaneous caspase activation. Int. J. Oncol. 20: 723-728
46. Ray S, Bullock G, Nunez G, Tang C, Ibrado AM, Huang Y and Bhalla K (1996) Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ. 7: 1617-1623
47. Schimmer AD, Hedley DW, Pham NA, Chow S and Minden MD (2001) BAD induces apoptosis in cells over-expressing Bcl-2 or Bcl-xL without loss of mitochondrial membrane potential. Leuk. Lymphoma 42: 429-443
48. Amati B, Littlewood TD, Evan GI and Land H (1993) The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 12: 5083-5087
49. Leppa S and Bohmann D (1999) Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18: 6158-6162
50. Treier M, Staszewski LM and Bohmann D (1994) Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78: 787-798
51. Salghetti SE, Muratani M, Wijnen H, Futcher B and Tansey WP (2000) Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc. Natl. Acad. Sci. USA 97: 3118-3123
52. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, and Hancock DC (1992) Induction of apoptosis in fibroblasts by c-Myc protein. Cell 69: 119-128
53. Tani E, Kitagawa H, Ikemoto H and Matsumoto T (2001) Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells. FEBS Lett. 504: 53-58
54. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ and Jones RJ (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83: 2038-2044
55. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV and Calabretta B (1997) Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and BCR/ABL antisense oligodeoxynucleotides. J. Natl. Cancer Inst. 89: 124-133
56. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R and Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038-1042
57. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037
58. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN and Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880
59. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R and Gambacorti-Passerini C (2000) Induction of resistance to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification. Blood 95: 1758-1766
60. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM and Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079
61. Weisberg E and Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95: 3498-3505
62. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S and Possinger K (2000) Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur. J. Haematol. 65: 221-236
63. Soligo D, Servida F, Delia D, Fontanella E, Lamorte G, Caneva L, Fumiatti R and Lambertenghi Deliliers G (2001) The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol. 113: 126-135
64. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ (1999) Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59: 2615-2622
65. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3: 231-234
66. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3: 222-225
67. Catzavelos C, Bhatacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Moravaprotzner I, Kapusta L et al. (1997) Decreased levels of the cell-cycle inhibitor p27(Kip1) protein - prognostic implications in primary breast cancer. Nat. Med. 3: 227-230
68. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA and Slingerland JM (1999) Reduced expression of the cell cycle inhibitor p27(Kip1) in non-small cell lung carcinoma: a prognostic factor independent of ras. Cancer Res. 59: 684-688
69. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM et al. (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-744
70. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I and Loh DY (1996) Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720
71. St. Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM and Kerbel RS (1996) Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2: 1204-1210
72. Eymin B, Haugg M, Droin N, Sordet O, Dimanche-Boitrel MT and Solary E (1999) p27(Kip1) induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 18: 1411-1418
73. Dimanche-Boitrel MT, Micheau O, France D, Hammann A, Duchamp O, Genne P and Solary E (2000) p27(Kip1) overexpression inhibits the growth and doxorubicin sensitivity of HT29 human colon cancer cells in vivo. Anticancer Res. 20: 849-852
74. Hiromura K, Pippin JW, Fero ML, Roberts JM and Shankland SJ (1999) Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J. Clin. Invest. 103: 597-604
75. Achenbach TV, Muller R and Slater EP (2000) Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27(Kip-1). Clin. Cancer Res. 6: 3006-3014
76. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L and Holyoake TL (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325
77. Park KH, Seol JL, Kim TY, Yoo CG, Kim YW, Han SK, Shim YS and Lee CT (2001) An adenovinus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res. 61: 6163-6169
78. Naruse I, Hoshino H, Dobashi K, Minato K, Saito R and Mori M (2000) Over-expression of p27Kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int. J. Cancer 88: 377-383
79. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139: 271-279